Related Experiment Video
Updated: Jun 14, 2025

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
Published on: May 24, 2024
Estrogen Replacement Therapy Decreases Associated Risk of Postoperative Venous Thromboemboli and Medical
Stephanie Zhao1, Mackenzie Kelly1, Spencer Smith1
1Department of Orthopaedics and Rehabilitation, Oregon Health & Science University, Portland, Oregon.
Background:
Estrogen replacement therapy (ERT) and total joint arthroplasty (TJA) are prevalent in the geriatric population, with limited evidence for how ERT influences postoperative outcomes. ERT is often held before arthroplasty due to the perceived risk for venous thromboembolism (VTE). Our primary aim was to investigate the relationship between ERT and VTE risk and secondarily to investigate major medical complications following TJA.
Methods:
A retrospective review was performed with a large national database querying International Classification of Diseases, tenth revision procedure codes, identifying 893,759 primary total hip arthroplasty (THA) and 1,660,909 total knee arthroplasty (TKA) procedures from 2015 to 2020. Of THAs, a cohort of 3,425 (3.5%) were prescribed ERT within 90 days before surgery and propensity matched to 6,850 control patients for age, tobacco use, obesity, and diabetes diagnosis. Of TKAs, a cohort of 7,409 (3.5%) was prescribed ERT and similarly propensity matched to 14,818 control patients. Propensity-matched data were qualified with adjusted odds ratios (OR) and 95% confidence intervals (CI) for deep vein thrombosis (DVT), pulmonary embolism (PE), and total medical complications.
Results:
After propensity matching, ERT use in THA demonstrated decreased risk of DVT (OR 0.52, CI 0.29 to 0.91, P = 0.028) but no difference in PE (OR 0.67, CI 0.34 to 1.32, P = 0.31). The ERT cohort had lower medical complications (OR 0.47, CI 0.31 to 0.73, P < 0.001). Among TKAs, ERT use was associated with decreased risk of DVT (OR 0.60, CI 0.44 to 0.82, P = 0.001), PE (OR 0.56, CI 0.37 to 0.83, P = 0.005), and medical complications (OR 0.53, CI 0.42 to 0.67, P < 0.001).
Conclusions:
The use of ERT with TJA is associated with decreased risk of VTE and major medical postoperative complications. These findings should be considered when counseling patients regarding the management of ERT when undergoing TJA.
More Related Videos
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
09:01Treatment of Ankle Osteoarthritis with Total Ankle Replacement Through a Lateral Transfibular Approach
Published on: January 24, 2018
Related Concept Videos
Venous Return
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...